NO20021147L - Polymorfismer i det humane hPXR genet og bruk av disse i diagnostiske og terapeutiske anvendelser - Google Patents

Polymorfismer i det humane hPXR genet og bruk av disse i diagnostiske og terapeutiske anvendelser

Info

Publication number
NO20021147L
NO20021147L NO20021147A NO20021147A NO20021147L NO 20021147 L NO20021147 L NO 20021147L NO 20021147 A NO20021147 A NO 20021147A NO 20021147 A NO20021147 A NO 20021147A NO 20021147 L NO20021147 L NO 20021147L
Authority
NO
Norway
Prior art keywords
hpxr
cyp3a7
cyp3a4
vectors
proteins
Prior art date
Application number
NO20021147A
Other languages
English (en)
Norwegian (no)
Other versions
NO20021147D0 (no
Inventor
Leszek Wojnowski
Elisabeth Hustert
Original Assignee
Epidauros Biotechnologie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epidauros Biotechnologie Ag filed Critical Epidauros Biotechnologie Ag
Publication of NO20021147D0 publication Critical patent/NO20021147D0/no
Publication of NO20021147L publication Critical patent/NO20021147L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20021147A 1999-09-10 2002-03-07 Polymorfismer i det humane hPXR genet og bruk av disse i diagnostiske og terapeutiske anvendelser NO20021147L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99118120A EP1088900A1 (de) 1999-09-10 1999-09-10 Polymorphismen des menschlichen CYP3A4, CYP3A7 und hPXR Gene, und ihre Anwendung in Diagnose und Therapie
PCT/EP2000/008827 WO2001020026A2 (en) 1999-09-10 2000-09-08 POLYMORPHISMS IN THE HUMAN hPXR GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS

Publications (2)

Publication Number Publication Date
NO20021147D0 NO20021147D0 (no) 2002-03-07
NO20021147L true NO20021147L (no) 2002-05-03

Family

ID=8238983

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20021147A NO20021147L (no) 1999-09-10 2002-03-07 Polymorfismer i det humane hPXR genet og bruk av disse i diagnostiske og terapeutiske anvendelser
NO20021146A NO20021146L (no) 1999-09-10 2002-03-07 Polymorfier i det humane CYP3A7 og CYP3A7 gener og deres anvendelse i diagnostikk og terapeutiske applikasjoner

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20021146A NO20021146L (no) 1999-09-10 2002-03-07 Polymorfier i det humane CYP3A7 og CYP3A7 gener og deres anvendelse i diagnostikk og terapeutiske applikasjoner

Country Status (9)

Country Link
US (2) US7655771B1 (de)
EP (3) EP1088900A1 (de)
JP (2) JP2003509063A (de)
AT (1) ATE378423T1 (de)
AU (2) AU7513300A (de)
CA (2) CA2379541A1 (de)
DE (1) DE60037126T2 (de)
NO (2) NO20021147L (de)
WO (2) WO2001020025A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP362898A0 (en) 1998-05-21 1998-06-11 University Of Sydney, The Xenobiotic induction of gene expression
AUPR116100A0 (en) 2000-11-01 2000-11-23 University Of Sydney, The P450 gene regulation
WO2002044213A1 (en) * 2000-11-28 2002-06-06 Zaphiropoulos Peter G New cytochrome p450 proteins and the corresponding dna sequences
JP2005510205A (ja) 2001-04-12 2005-04-21 ゼノジェン コーポレイション チトクロム発現に関連するマウスおよびヒト転写制御エレメントの単離および同定
JP2003304896A (ja) 2002-04-15 2003-10-28 Yasushi Yamazoe ヒトｃｙｐ３ａ誘導能の測定法
WO2004038404A2 (en) * 2002-10-28 2004-05-06 Pharmacia Italia Spa Method for optimizing therapeutic efficacy of nemorubicin
US7759541B2 (en) 2004-12-13 2010-07-20 Iti Life Sciences Transgenic animals for assessing drug metabolism and toxicity
JP2007119359A (ja) * 2005-10-25 2007-05-17 Fujifilm Corp 癌抑制剤
CA2667228C (en) * 2006-10-23 2015-07-14 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
WO2010111600A1 (en) * 2009-03-26 2010-09-30 The Ohio State University Research Foundation Polymorphism in cyp3a4 gene affecting drug metabolizing and uses thereof
US9938576B1 (en) 2012-09-21 2018-04-10 Ohio State Innovation Foundation Materials and methods for determining metabolizer status in humans

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9001181D0 (en) * 1990-01-18 1990-03-21 Imp Cancer Res Tech Genetic assay
JP3564579B2 (ja) * 1994-05-06 2004-09-15 大塚製薬株式会社 ヒトチトクロームｐ４５０２ｄ６遺伝子多型の検出方法
FR2733251B1 (fr) * 1995-04-18 1997-07-04 Inst Nat Sante Rech Med Depistage du glaucome juvenile
US6025131A (en) * 1996-10-23 2000-02-15 E. I. Du Pont De Namours And Company Facile method for identifying regulated promoters
WO1998020165A2 (en) * 1996-11-06 1998-05-14 Whitehead Institute For Biomedical Research Biallelic markers
WO1999005292A1 (en) * 1997-07-22 1999-02-04 Chugai Seiyaku Kabushiki Kaisha Method for gene screening with the use of nuclear receptors
US6432639B1 (en) * 1997-09-10 2002-08-13 Dna Sciences Laboratories, Inc. Isolated CYP3A4 nucleic acid molecules and detection methods
JP2002535241A (ja) * 1998-03-27 2002-10-22 グラクソ グループ リミテッド オーファン核内受容体
US6821724B1 (en) * 1998-09-17 2004-11-23 Affymetrix, Inc. Methods of genetic analysis using nucleic acid arrays
US6183963B1 (en) * 1998-10-23 2001-02-06 Signalgene Detection of CYP1A1, CYP3A4, CYP2D6 and NAT2 variants by PCR-allele-specific oligonucleotide (ASO) assay

Also Published As

Publication number Publication date
AU7001800A (en) 2001-04-17
CA2379541A1 (en) 2001-03-22
WO2001020025A3 (en) 2001-10-11
WO2001020025A2 (en) 2001-03-22
NO20021146D0 (no) 2002-03-07
AU7513300A (en) 2001-04-17
CA2381066A1 (en) 2001-03-22
ATE378423T1 (de) 2007-11-15
WO2001020026A3 (en) 2001-12-13
EP1210462B1 (de) 2007-11-14
NO20021146L (no) 2002-04-15
US7122652B1 (en) 2006-10-17
US7655771B1 (en) 2010-02-02
EP1210462A2 (de) 2002-06-05
EP1088900A1 (de) 2001-04-04
DE60037126T2 (de) 2008-09-18
DE60037126D1 (de) 2007-12-27
WO2001020026A2 (en) 2001-03-22
EP1210463A2 (de) 2002-06-05
NO20021147D0 (no) 2002-03-07
JP2003509064A (ja) 2003-03-11
JP2003509063A (ja) 2003-03-11

Similar Documents

Publication Publication Date Title
Orlanski et al. Tissue-specific DNA demethylation is required for proper B-cell differentiation and function
Gerber et al. Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations
Yin et al. The gene network underlying hypodontia
WO2003087368A3 (en) Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification
NO20021147L (no) Polymorfismer i det humane hPXR genet og bruk av disse i diagnostiske og terapeutiske anvendelser
ATE371738T1 (de) Mittel und verfahren zur diagnose und behandlung affektiver störungen
DK1232260T3 (da) Polymorfi i det humane MDR-1-gen og anvendelser deraf
Pal et al. Concomitant gain and loss of function pathomechanisms in C9ORF72 amyotrophic lateral sclerosis
ATE513929T1 (de) Gene mit einfluss auf die menschliche gedächtnisleistung
Pang et al. High-throughput sequencing offers new insights into 5-hydroxymethylcytosine
Cico et al. Enhancers and their dynamics during hematopoietic differentiation and emerging strategies for therapeutic action
WO2004050860A3 (en) Compositions, splice variants and methods relating to colon specific genes and proteins
DK1272663T3 (da) Polymorfier i det humane CYP2B6-gen og deres anvendelse ved diagnostiske og terapeutiske anvendelser
WO2005017102A3 (en) Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
DE50312502D1 (de) Screeningverfahren zum identifizieren protektiver substanzen für die behandlung neurodegenerativer und/oder ischämischer erkrankungen
Abel et al. Trem2R47H and reduced TREM2 expression both mimic human Alzheimer’s disease signatures in mice
Pal et al. High content live profiling reveals concomitant gain and loss of function pathomechanisms in C9ORF72 amyotrophic lateral sclerosis
Talbot et al. Musculoskeletal diseases: from complex genetics to therapy
Rothwell et al. Future Directions for Animal Models in Behavior Genetics
Holcomb et al. GRHD PLANNING COMMITTEE
WO2003102137A3 (en) Compositions and methods relating to lung specific genes and proteins
WO2005044075A3 (en) Compositions, splice variants and methods relating to breast specific genes and proteins
WO2003060145A3 (en) Compositions and methods relating to pancreatic specific genes and proteins
WO2004089301A3 (en) Compositions, splice variants and methods relating to colon specific genes and proteins
SE0303268D0 (sv) Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof